CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients

Abstract

Background:CD133 has been identified as a putative cancer stem cell marker in colorectal cancer (CRC). However, the clinicopathological and prognostic significance of CD133 in CRC patients remains controversial. Thus, we conducted a meta-analysis to quantitatively evaluate the above issues.Methods:We collected a comprehensive literature search from PubMed, Web of Science, and Embase database up to September 20, 2016 examining CD133 and clinical features of colorectal cancer patients. We used the odds ratio (OR) with 95% confidence interval (CI) to estimate the effects by overall and stratified analysis.Results:The overall result of our meta-analysis indicated that CD133 expression was positively correlated with T category, distant metastasis, lymphatic invasion, and vascular invasion. Moreover, patients with higher CD133 expression had a poorer overall survival (OS) (HR=2.01, P < .001) and a lower 5-year OS rate (OR = 3.26, P < .001) than those with lower expression. Disease-free survival (DFS) and 5-year DFS rate were similar with the above results. Though the correlation between CD133 expression with the clinical characteristic was not positive in some ways when we analyzed the different subgroup. The prognostic value of CD133 expression for 5-year OS rate of CRC patients was noticeable in spite of different patients’ region, multiple antibodies used in studies, various cut-off values of CD133 expression, and adjuvant therapy situation of patients.Conclusion:CD133 is a useful predictive or prognostic biomarker for CRC in clinical assessment and may serve as a potential therapeutic target for CRC.

Microenvironmentally-driven Plasticity of CD44 isoform expression determines Engraftment and Stem-like Phenotype in CRC cell lines

“…Problems and controversies still arise from (i) inconsistent semantics and terminology in the field, (ii) putative, functionally non-linked or poorly-defined surrogate markers despite their potential prognostic and predictive value - this applies to many CD surface markers, e.g. the transmembrane glycoprotein CD133 studied herein 53 , 54 , and (iii) splice variants and posttranslational modifications of proposed CSC surrogate markers that are often not sufficiently discriminated in preclinical and clinical studies such as CD44, our second marker of interest 55 .…”

Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets

“…One example indicating CSCs contribution to drug resistance is that when tumors were treated with conventional anti-cancer drugs such as cisplatin, small number of cancer cells survived and the proportion of cells showing the CSC properties significantly increased [38,39] . Another example is that patient prognosis is much worse when cancer cells in tumor strongly express CSC markers like CD133 [40][41][42][43][44] . Furthermore, CSCs isolated from clinical breast tumor samples were reported to show strong resistance to various chemotherapeutic drugs [42] .…”

Multiplex Immunohistochemistry Indicates Biomarkers in Colorectal Cancer

“…As for the clinical status of CRC patients, Kashihara [19] demonstrated that high CD133 expression in CRC correlated with poor clinical outcomes. Huang's group [20] confirmed from existing 37 studies that CD133 would be served as a poor predictive indicator in CRC patients, due to CD133 overexpression positively associated with late T category, distant metastasis, lymphatic invasion, vascular invasion, as well as with lower 5-year Overall Survival/Disease-Free Survival (OS/DFS) rate and higher HR of OS/DFS in CRC patients. This finding was almost in line with the study by Wang's team [21] .…”